Stay updated with breaking news from Trials Consortium. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Company's lead drug candidate PrimeC is currently being evaluated in a Phase IIb trial, with topline data expected in mid-2023CAMBRIDGE, Mass., Se...
Researchers using machine learning find neurodegenerative disease progression can fall into newly identified patterns. The work, led by members of the MIT-IBM Watson AI Lab, may help predict patient prognoses, inform clinical trial designs, and discover underlying disease causes.
New drug reduces tumor volume and pain in patients with neurofibromatosis type 1 Based on preclinical studies of an investigational drug to treat peripheral nerve tumors, researchers at Children's Hospital of Philadelphia (CHOP) as part of the Neurofibromatosis Clinical Trials Consortium have shown that the drug, cabozantinib, reduces tumor volume and pain in patients with the genetic disorder neurofibromatosis type 1 (NF1). The results of the Phase 2 clinical trial, co-chaired by Michael J. Fisher, MD at CHOP, were published recently in Nature Medicine. "This is the second class of drugs to...